Cargando…
The Role of Donor Leukocyte Infusions in the Treatment of Relapsed Acute Leukemia after Allogeneic Stem Cell Transplantation: A Retrospective Analysis
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment offered for acute leukemias with potential curative capability. One of the main reasons of treatment failure in patients after allo-HSCT is return of the primary disease. This study aimed to evaluate the...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305269/ https://www.ncbi.nlm.nih.gov/pubmed/30595820 |
_version_ | 1783382524553068544 |
---|---|
author | Vaezi, Mohammad Zokaasadi, Mohammad Shahsavari Pour, Shervin Kasaeian, Amir Nikbakht, Mohsen Kamranzadeh Fumani, Hosein Alimoghaddam, Kamran Ghavamzadeh, Ardeshir |
author_facet | Vaezi, Mohammad Zokaasadi, Mohammad Shahsavari Pour, Shervin Kasaeian, Amir Nikbakht, Mohsen Kamranzadeh Fumani, Hosein Alimoghaddam, Kamran Ghavamzadeh, Ardeshir |
author_sort | Vaezi, Mohammad |
collection | PubMed |
description | Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment offered for acute leukemias with potential curative capability. One of the main reasons of treatment failure in patients after allo-HSCT is return of the primary disease. This study aimed to evaluate the role of different modalities available to treat the patients with relapsed acute leukemia after allo-HSCT, focusing mainly on donor leukocyte infusions (DLIs). Materials and Methods: This study included 277 patients who relapsed after myeloablative allo-HSCT between February 2003 and February 2015. Treatment option was offered to all patients, but it was not accepted by about one-third of the study participants. Treated patients were categorized based on receipt of DLI (DLI-based vs. non DLI-based). The effect of treatment in all patients and then the effect of DLI among the treated group was evaluated. Kaplan-Meier method was used for calculating survival rates. All patients were relapsed cases, thus only overall survival (OS) was calculated. Results: One hundred and forty-five ALL patients and 132 AML patients were included in the study. One year survival rate for treated patients was 25.13% and for patients who received best supportive care was 2.79% (P<0.001). The difference was significant in both AML and ALL groups. Using DLI-based treatments were accompanied by a noticeably superior outcome. Hazard ratio was 0.43 (0.29-0.63) for DLI-based treatments (P<0.001). Conclusion: Despite the poor prognosis of relapsed acute leukemia after HSCT, it seems that treatment interventions and, especially DLI-based treatments, can be of substantial benefit for patients. |
format | Online Article Text |
id | pubmed-6305269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center |
record_format | MEDLINE/PubMed |
spelling | pubmed-63052692018-12-28 The Role of Donor Leukocyte Infusions in the Treatment of Relapsed Acute Leukemia after Allogeneic Stem Cell Transplantation: A Retrospective Analysis Vaezi, Mohammad Zokaasadi, Mohammad Shahsavari Pour, Shervin Kasaeian, Amir Nikbakht, Mohsen Kamranzadeh Fumani, Hosein Alimoghaddam, Kamran Ghavamzadeh, Ardeshir Int J Hematol Oncol Stem Cell Res Original Article Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment offered for acute leukemias with potential curative capability. One of the main reasons of treatment failure in patients after allo-HSCT is return of the primary disease. This study aimed to evaluate the role of different modalities available to treat the patients with relapsed acute leukemia after allo-HSCT, focusing mainly on donor leukocyte infusions (DLIs). Materials and Methods: This study included 277 patients who relapsed after myeloablative allo-HSCT between February 2003 and February 2015. Treatment option was offered to all patients, but it was not accepted by about one-third of the study participants. Treated patients were categorized based on receipt of DLI (DLI-based vs. non DLI-based). The effect of treatment in all patients and then the effect of DLI among the treated group was evaluated. Kaplan-Meier method was used for calculating survival rates. All patients were relapsed cases, thus only overall survival (OS) was calculated. Results: One hundred and forty-five ALL patients and 132 AML patients were included in the study. One year survival rate for treated patients was 25.13% and for patients who received best supportive care was 2.79% (P<0.001). The difference was significant in both AML and ALL groups. Using DLI-based treatments were accompanied by a noticeably superior outcome. Hazard ratio was 0.43 (0.29-0.63) for DLI-based treatments (P<0.001). Conclusion: Despite the poor prognosis of relapsed acute leukemia after HSCT, it seems that treatment interventions and, especially DLI-based treatments, can be of substantial benefit for patients. Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2018-07-01 /pmc/articles/PMC6305269/ /pubmed/30595820 Text en Copyright : © International Journal of Hematology-Oncology and Stem Cell Research & Tehran University of Medical Sciences This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Vaezi, Mohammad Zokaasadi, Mohammad Shahsavari Pour, Shervin Kasaeian, Amir Nikbakht, Mohsen Kamranzadeh Fumani, Hosein Alimoghaddam, Kamran Ghavamzadeh, Ardeshir The Role of Donor Leukocyte Infusions in the Treatment of Relapsed Acute Leukemia after Allogeneic Stem Cell Transplantation: A Retrospective Analysis |
title | The Role of Donor Leukocyte Infusions in the Treatment of Relapsed Acute Leukemia after Allogeneic Stem Cell Transplantation: A Retrospective Analysis |
title_full | The Role of Donor Leukocyte Infusions in the Treatment of Relapsed Acute Leukemia after Allogeneic Stem Cell Transplantation: A Retrospective Analysis |
title_fullStr | The Role of Donor Leukocyte Infusions in the Treatment of Relapsed Acute Leukemia after Allogeneic Stem Cell Transplantation: A Retrospective Analysis |
title_full_unstemmed | The Role of Donor Leukocyte Infusions in the Treatment of Relapsed Acute Leukemia after Allogeneic Stem Cell Transplantation: A Retrospective Analysis |
title_short | The Role of Donor Leukocyte Infusions in the Treatment of Relapsed Acute Leukemia after Allogeneic Stem Cell Transplantation: A Retrospective Analysis |
title_sort | role of donor leukocyte infusions in the treatment of relapsed acute leukemia after allogeneic stem cell transplantation: a retrospective analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305269/ https://www.ncbi.nlm.nih.gov/pubmed/30595820 |
work_keys_str_mv | AT vaezimohammad theroleofdonorleukocyteinfusionsinthetreatmentofrelapsedacuteleukemiaafterallogeneicstemcelltransplantationaretrospectiveanalysis AT zokaasadimohammad theroleofdonorleukocyteinfusionsinthetreatmentofrelapsedacuteleukemiaafterallogeneicstemcelltransplantationaretrospectiveanalysis AT shahsavaripourshervin theroleofdonorleukocyteinfusionsinthetreatmentofrelapsedacuteleukemiaafterallogeneicstemcelltransplantationaretrospectiveanalysis AT kasaeianamir theroleofdonorleukocyteinfusionsinthetreatmentofrelapsedacuteleukemiaafterallogeneicstemcelltransplantationaretrospectiveanalysis AT nikbakhtmohsen theroleofdonorleukocyteinfusionsinthetreatmentofrelapsedacuteleukemiaafterallogeneicstemcelltransplantationaretrospectiveanalysis AT kamranzadehfumanihosein theroleofdonorleukocyteinfusionsinthetreatmentofrelapsedacuteleukemiaafterallogeneicstemcelltransplantationaretrospectiveanalysis AT alimoghaddamkamran theroleofdonorleukocyteinfusionsinthetreatmentofrelapsedacuteleukemiaafterallogeneicstemcelltransplantationaretrospectiveanalysis AT ghavamzadehardeshir theroleofdonorleukocyteinfusionsinthetreatmentofrelapsedacuteleukemiaafterallogeneicstemcelltransplantationaretrospectiveanalysis AT vaezimohammad roleofdonorleukocyteinfusionsinthetreatmentofrelapsedacuteleukemiaafterallogeneicstemcelltransplantationaretrospectiveanalysis AT zokaasadimohammad roleofdonorleukocyteinfusionsinthetreatmentofrelapsedacuteleukemiaafterallogeneicstemcelltransplantationaretrospectiveanalysis AT shahsavaripourshervin roleofdonorleukocyteinfusionsinthetreatmentofrelapsedacuteleukemiaafterallogeneicstemcelltransplantationaretrospectiveanalysis AT kasaeianamir roleofdonorleukocyteinfusionsinthetreatmentofrelapsedacuteleukemiaafterallogeneicstemcelltransplantationaretrospectiveanalysis AT nikbakhtmohsen roleofdonorleukocyteinfusionsinthetreatmentofrelapsedacuteleukemiaafterallogeneicstemcelltransplantationaretrospectiveanalysis AT kamranzadehfumanihosein roleofdonorleukocyteinfusionsinthetreatmentofrelapsedacuteleukemiaafterallogeneicstemcelltransplantationaretrospectiveanalysis AT alimoghaddamkamran roleofdonorleukocyteinfusionsinthetreatmentofrelapsedacuteleukemiaafterallogeneicstemcelltransplantationaretrospectiveanalysis AT ghavamzadehardeshir roleofdonorleukocyteinfusionsinthetreatmentofrelapsedacuteleukemiaafterallogeneicstemcelltransplantationaretrospectiveanalysis |